Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.

Eur J Nucl Med Mol ImagingJun 19, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Claudia Leslie, Zeyad Al-Ogaili, Leone Oh et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase I trial evaluated the safety and maximum tolerated dose (MTD) of capecitabine combined with Lutetium-177-PSMA I&T (Lu-PSMA) in 12 men with metastatic castration-resistant prostate cancer (mCRPC). The MTD was established at 1000 mg/m², with a PSA-50 response rate of 50% and a PSA-progression free survival of 4.7 months.

Key findings

  • The maximum tolerated dose of capecitabine was established at 1000 mg/m².
  • The PSA-50 response rate was 50% across dose levels.
  • PSA-progression free survival was 4.7 months (95% CI 2.3-21.6).
  • Common treatment-related adverse events included nausea, fatigue, and diarrhoea.

Why it matters

The combination of capecitabine and Lu-PSMA may enhance treatment options for patients with heavily pre-treated mCRPC, potentially improving therapeutic outcomes in this challenging population.

Source

PubMed · PMID 42315637Free full text on PubMed Central

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.